Royal Bank of Canada
GTBP icon

Royal Bank of Canada’s GT Biopharma GTBP Stock Holding History

Royal Bank of Canada’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
+126
New +$69 ﹤0.01% 7356
2024
Q4 		– Sell
-5
Closed – – 7028
2024
Q3 		$0 Sell
5
-2
-29% -$5 ﹤0.01% 7078
2024
Q2 		$0 Hold
7
– – ﹤0.01% 7246
2024
Q1 		$0 Sell
7
-66
-90% -$349 ﹤0.01% 7233
2023
Q4 		$0 Sell
73
-8
-10% -$58 ﹤0.01% 7306
2023
Q3 		$0 Sell
81
-46
-36% -$380 ﹤0.01% 7276
2023
Q2 		$2K Buy
127
+43
+51% +$446 ﹤0.01% 6874
2023
Q1 		$1K Sell
84
-9,315
-99% -$213K ﹤0.01% 6892
2022
Q4 		$250K Buy
9,399
+9,330
+13,522% +$466K ﹤0.01% 4679
2022
Q3 		$3K Buy
69
+4
+6% +$306 ﹤0.01% 6890
2022
Q2 		$6K Sell
65
-37
-36% -$2.8K ﹤0.01% 6578
2022
Q1 		$9K Sell
102
-111
-52% -$9.79K ﹤0.01% 6993
2021
Q4 		$20K Buy
213
+75
+54% +$11.2K ﹤0.01% 6801
2021
Q3 		$28K Buy
138
+18
+15% +$5.42K ﹤0.01% 6501
2021
Q2 		$55K Sell
120
-698
-85% -$290K ﹤0.01% 5972
2021
Q1 		$167K Buy
+818
New +$143K ﹤0.01% 5088

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Royal Bank of Canada's GTBP Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in GT Biopharma (GTBP) in Q1 2026: 126 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #7356 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in GTBP as recently as Q3 2024.

Royal Bank of Canada first reported a position in GTBP in Q1 2021 and has held it in 16 quarters since. The position peaked at $250K in Q4 2022. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Royal Bank of Canada held 126 shares of GT Biopharma worth $0 as of Q1 2026.
  • GT Biopharma was a new Royal Bank of Canada position in Q1 2026.
  • GT Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7356 holding.
  • Royal Bank of Canada first reported a position in GT Biopharma in Q1 2021 and has held it in 16 quarters since.
  • Royal Bank of Canada's GT Biopharma position peaked at $250K in Q4 2022.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.